These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 23959319)

  • 1. Clinical pharmacodynamic index identification for micafungin in esophageal candidiasis: dosing strategy optimization.
    Andes DR; Reynolds DK; Van Wart SA; Lepak AJ; Kovanda LL; Bhavnani SM
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5714-6. PubMed ID: 23959319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Extended-Interval Dosing of Micafungin Evaluated Using a Pharmacokinetic/Pharmacodynamic Study with Humanized Doses in Mice.
    Lepak A; Marchillo K; VanHecker J; Azie N; Andes D
    Antimicrob Agents Chemother; 2016 Jan; 60(1):674-7. PubMed ID: 26552968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients.
    Maseda E; Grau S; Luque S; Castillo-Mafla MP; Suárez-de-la-Rica A; Montero-Feijoo A; Salgado P; Gimenez MJ; García-Bernedo CA; Gilsanz F; Roberts JA
    Crit Care; 2018 Apr; 22(1):94. PubMed ID: 29655372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.
    Arendrup MC; Perlin DS; Jensen RH; Howard SJ; Goodwin J; Hope W
    Antimicrob Agents Chemother; 2012 May; 56(5):2435-42. PubMed ID: 22354305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection.
    Lepak AJ; Zhao M; Berkow EL; Lockhart SR; Andes DR
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584152
    [No Abstract]   [Full Text] [Related]  

  • 6. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.
    Andes DR; Diekema DJ; Pfaller MA; Marchillo K; Bohrmueller J
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3497-503. PubMed ID: 18625768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.
    Andes D; Diekema DJ; Pfaller MA; Bohrmuller J; Marchillo K; Lepak A
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2497-506. PubMed ID: 20385855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits.
    Petraitiene R; Petraitis V; Hope WW; Walsh TJ
    Clin Infect Dis; 2015 Dec; 61 Suppl 6(Suppl 6):S643-51. PubMed ID: 26567283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.
    Boonstra JM; van der Elst KC; Veringa A; Jongedijk EM; Brüggemann RJ; Koster RA; Kampinga GA; Kosterink JG; van der Werf TS; Zijlstra JG; Touw DJ; Alffenaar JWC
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections.
    Ikawa K; Nomura K; Morikawa N; Ikeda K; Taniwaki M
    J Antimicrob Chemother; 2009 Oct; 64(4):840-4. PubMed ID: 19700475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections.
    Scott LJ
    Drugs; 2012 Nov; 72(16):2141-65. PubMed ID: 23083111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between the EUCAST procedure and the Etest for determination of the susceptibility of Candida species isolates to micafungin.
    Marcos-Zambrano LJ; Escribano P; Rueda C; Zaragoza Ó; Bouza E; Guinea J
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5767-70. PubMed ID: 23979756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients.
    Martial LC; Ter Heine R; Schouten JA; Hunfeld NG; van Leeuwen HJ; Verweij PE; de Lange DW; Pickkers P; Brüggemann RJ
    Clin Pharmacokinet; 2017 Oct; 56(10):1197-1206. PubMed ID: 28144840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single or 2-Dose Micafungin Regimen for Treatment of Invasive Candidiasis: Therapia Sterilisans Magna!
    Gumbo T
    Clin Infect Dis; 2015 Dec; 61 Suppl 6():S635-42. PubMed ID: 26567282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of micafungin in neonates and young infants.
    Hope WW; Smith PB; Arrieta A; Buell DN; Roy M; Kaibara A; Walsh TJ; Cohen-Wolkowiez M; Benjamin DK
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2633-7. PubMed ID: 20308367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disseminated Candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin.
    Slater JL; Howard SJ; Sharp A; Goodwin J; Gregson LM; Alastruey-Izquierdo A; Arendrup MC; Warn PA; Perlin DS; Hope WW
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3075-83. PubMed ID: 21502627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and Safety of Micafungin in Infants Supported With Extracorporeal Membrane Oxygenation.
    Autmizguine J; Hornik CP; Benjamin DK; Brouwer KL; Hupp SR; Cohen-Wolkowiez M; Watt KM
    Pediatr Infect Dis J; 2016 Nov; 35(11):1204-1210. PubMed ID: 27314826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts.
    Howard SJ; Livermore J; Sharp A; Goodwin J; Gregson L; Alastruey-Izquierdo A; Perlin DS; Warn PA; Hope WW
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4880-7. PubMed ID: 21807969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.
    Lepak A; Castanheira M; Diekema D; Pfaller M; Andes D
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5875-82. PubMed ID: 22948870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.
    Andes D; Ambrose PG; Hammel JP; Van Wart SA; Iyer V; Reynolds DK; Buell DN; Kovanda LL; Bhavnani SM
    Antimicrob Agents Chemother; 2011 May; 55(5):2113-21. PubMed ID: 21300835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.